ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Ab Science

Ab Science (AB)

0.79
-0.01
(-1.25%)
Closed November 25 11:30AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.79
Bid
0.774
Ask
0.795
Volume
34,797
0.77 Day's Range 0.80
0.77 52 Week Range 4.465
Market Cap
Previous Close
0.80
Open
0.79
Last Trade
400
@
0.79
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
36,173
Shares Outstanding
52,071,069
Dividend Yield
-
PE Ratio
-3.43
Earnings Per Share (EPS)
-0.23
Revenue
970k
Net Profit
-11.99M

About Ab Science

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Paris, Paris, Fra
Founded
-
Ab Science is listed in the Pharmaceutical Preparations sector of the Euronext with ticker AB. The last closing price for Ab Science was 0.80 €. Over the last year, Ab Science shares have traded in a share price range of 0.77 € to 4.465 €.

Ab Science currently has 52,071,069 shares outstanding. The market capitalization of Ab Science is 41.66 € million. Ab Science has a price to earnings ratio (PE ratio) of -3.43.

AB Latest News

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN...

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS...

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S...

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL...

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE...

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024...

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science

AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science          COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities          PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS...

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by...

AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros

AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REALISE LE REGLEMENT LIVRAISON...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.095-10.73446327680.8850.890.77657790.82608986DE
4-0.176-18.21946169770.9661.050.77464400.91238887DE
12-0.26-24.76190476191.051.0660.77361730.96177527DE
26-1.295-62.11031175062.0852.1550.77704761.21972209DE
52-2.03-71.98581560282.824.4650.77997432.21709468DE
156-11.64-93.644408688712.4313.340.77955024.68102052DE
260-4.25-84.32539682545.0421.750.771448408.45773046DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ATOAtos SE
0.3102 €
(98.85%)
5.52M
ALIMOGroupimo
0.276 €
(46.03%)
100
ALROCRoctool
0.36 €
(23.29%)
109.71k
ALARFAdeunis
0.782 €
(20.68%)
3.34k
SOISOITEC
84.75 €
(15.78%)
345.37k
EMGDSEuromedis DS
0.0006 €
(-93.33%)
199.36k
BIDSGascogne DS
0.0024 €
(-52.00%)
75.95k
ALCHIAlchimie
0.266 €
(-16.09%)
71.82k
ALDOLDolfines
1.95 €
(-15.22%)
23.68k
ALICRICeram
0.402 €
(-12.61%)
493
BCPBanco Comercial Portugues SA
0.4471 €
(0.56%)
137.15M
EDPEDP SA
3.515 €
(0.98%)
38.88M
ALNEVNeovacs
0.0002 €
(0.00%)
33.1M
ATOAtos SE
0.3102 €
(98.85%)
29.05M
KPNKoninklijke KPN NV
3.65 €
(0.83%)
21.8M

Discussion

View Full Feed
johnydollar johnydollar 1 minute ago
Yeah, they wish........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹
DBMM
Go Hawks13 Go Hawks13 1 minute ago
It’s at .35 cents a share split adjusted. Lol lol lol lol
FCEL
Clark6290 Clark6290 2 minutes ago
Pencil neck
FNMA
glenn1919 glenn1919 2 minutes ago
BENF................IBG........................https://stockcharts.com/h-sc/ui?s=IBG&p=D&yr=0&mn=2&dy=12&id=p84071410134
BENF IBG
Monksdream Monksdream 2 minutes ago
WLGS, new 52 week high
https://investorshub.advfn.com/uimage/uploads/2024/11/25/lyhphIMG_3472.gif
WLGS
OrbitWitch50 OrbitWitch50 2 minutes ago
What do you think it may be? I'm expecting quarters. Hard to tell without Kaboomracks financials.
CGAC
Mr Smith 34 Mr Smith 34 2 minutes ago
So in others words, you have absolutely no idea what you are talking about and couldn't explain your way out of a paper bag.
Back to the kiddie table with you sonny jim.
SPZI
laraz5 laraz5 2 minutes ago
While we are at it where is Mike's official statement that Joe Pignatiello never had any involvement in Xcelerate Inc?

Would it not be refreshing to hear Joe never worked for Xcelerate and never received any form of payments?

That would be refreshing?

XCRT
threewheeler threewheeler 2 minutes ago
KRTL 3 MMs trying for shares, too late, weak hands aren't getting re-filled any more, slap the ask or pay more tomorrow with PRs scheduled
KRTL
strippa strippa 2 minutes ago
Dave just posted on X - https://x.com/Dave_Oswald_CEO/status/1861136595639816240
BLEG
bar1080 bar1080 2 minutes ago
I don't own M.
IPO$ IPO$ 3 minutes ago
What's the story on this coin? Any fundamentals?
XRPUSD
Teliz2009 Teliz2009 3 minutes ago
So........ you're completely out?
WRAP
I-Glow I-Glow 3 minutes ago
Unsolicited Quotes Only actually means that Spooz hasn't filed a Form 211 with FINRA.

A Form 211 has to be filed by a MM or a broker/dealer.

It has nothing to do with MMs manipulating the price.

IG
SPZI
glenn1919 glenn1919 3 minutes ago
IBG...................................https://stockcharts.com/h-sc/ui?s=IBG&p=W&b=5&g=0&id=p86431144783
IBG
lizzy241 lizzy241 3 minutes ago
Nuke, I've been tracking my expry dates, they seem to be pretty consistent being about 1 yr to 1 1/2yr out. My bad, my brand V bottle states manufactured for Amarin pharma not by. Distributed by: Amarin Pharma Inc. Bridgewater, NJ
AMRN
barrydingle barrydingle 3 minutes ago
He told you about Lazzaro and Rothstein too.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175439210
NWGC
gdog gdog 4 minutes ago
The Harbs days were the good old days I message him a couple times a yr, one of the best guys I know last time I sent he never responded so not sure what up there. as far a cin and Bull just a couple hateful poeple is all I can say
NLST
Hoghead7 Hoghead7 4 minutes ago
Average volume, up 30%, and 100% up from recent post-split low. Market Cap (shares) still vastly undervalued equal to $.36 pre-split or about $220-$225M market cap. Cash and equivalents are $300M with $1.2B backlog. $9B market cap in February 2021. New deals with Canadian Nuclear Labs and Korea N
FCEL
ExtremelyBullishZig ExtremelyBullishZig 4 minutes ago
Will they hear your prayers?
AVXL
Think1st Think1st 4 minutes ago
Each filing costs money. This is the tenth filing, yet zero business. How does he keep paying money to file , on a business that has no business
Imo
This is insane
INQD
gp22 gp22 4 minutes ago
$MOB @ $1.40s: Nano-float AI Drone play...Another ripper target.
MOB
fuagf fuagf 4 minutes ago
Corruption U.S.A. Inc. - Trump lawyers investigate allegations that top aide sought financial gain from influence with president-elect, sources say

"Number of Trump Allies Facing Election Interference Charges Keeps Growing
[...]What’s more, Mr. Trump’s top legal strategist,
glenn1919 glenn1919 4 minutes ago
UP......BFRG......BLND.......https://stockcharts.com/h-sc/ui?s=BFRG&p=D&yr=0&mn=2&dy=12&id=p84071410134
BFRG BLND

Your Recent History

Delayed Upgrade Clock